Get to know our clinical trials
A Phase 2 Study of Petosemtamab in Combination with Docetaxel as Second-Line or Pembrolizumab as First-Line Metastatic Treatment in Adults with NSCLC.
YOU ARE INVITED TO PARTICIPATE IN THIS STUDY BECAUSE YOU HAVE METASTATIC LUNG CANCER. TO PARTICIPATE IN THIS STUDY, YOUR LUNG CANCER MUST EXPRESS A PROTEIN CALLED PROGRAMMED DEATH-LIGAND 1 (PD-L1). PD-L1 IS A PROTEIN FOUND ON CANCER CELLS THAT CAN PREVENT THE BODY’S IMMUNE SYSTEM FROM ATTACKING THE CANCER CELLS. PEMBROLIZUMAB IS A TREATMENT THAT BLOCKS THE EFFECTS OF PD-L1 AND ALLOWS THE IMMUNE SYSTEM TO ATTACK AND KILL CANCER CELLS. YOUR DISEASE MUST HAVE A PD-L1 SCORE OF ≥50%. THIS RESULT COMES FROM A TEST THAT WAS PERFORMED AS PART OF YOUR USUAL CARE, AND YOU WILL NOT NEED TO UNDERGO ANY ADDITIONAL TESTING FOR THIS AS PART OF THIS STUDY.
Technical Summary
- A PHASE II STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PETOSEMTAMAB IN COMBINATION WITH DOCETAXEL AS A SECOND-LINE TREATMENT IN ADULTS WITH METASTATIC NON-SMALL CELL LUNG CANCER, OR IN COMBINATION WITH PEMBROLIZUMAB AS A FIRST-LINE TREATMENT.
- Code EudraCT: 2025-522867-13
- Protocol number: MCLA-158-CL04
- Promoter: Merus N.V.
- Molecule/Drug: Petosemtamab en combinación con docetaxel
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.